Peptilotbeta

Latest research

The peptide literature, summarized and graded.

Every paper distilled to a plain-language summary with an honest evidence grade — from strong human trials to animal-only signals. 2 papers indexed and counting.

Ask the literature →
Sourceallpaperstrialsyoutube
Evidenceallreviewinsufficientlimited humananimal onlymoderate humanin vitro onlystrong humanpreclinical mixed
CompoundGLP-1semaglutidetirzepatideretatrutidethymosin beta-4BPC-157TB-500cagrilintidesermorelinsurvodutideGHK-CumazdutidePT-141melanotan
Filtered by #thymosin alpha-1 · clear
In vitro

Thymosin α1-induced secretion of the IL-15/RA complex by THP-1-derived dendritic cells restrains HIV latency <i>in vitro</i>.

This in vitro study investigated how Thymosin α1 (Tα1) may help reduce the HIV-1 viral reservoir by acting on immune cells. Researchers differentiated THP-1 cells into monocyte-derived dendritic cells (MoDCs) and co-cultured them with peripheral blood mononuclear cells (PBMCs) obtained from people living with HIV-1 (PLWH). The study found that Tα1 stimulation of MoDCs triggered secretion of the IL-15/IL-15 receptor alpha (IL-15/RA) complex, which was associated with enhanced CD8+ T cell and NK cell functionality — including increased secretion of IFN-γ, TNF-α, and granzyme B (GZMB) — along with reductions in intracellular HIV-1 p24 levels and integrated HIV-1 DNA. Notably, these effects were only observed in PBMCs from immunological responders (CD4+ T cell count >350 cells/µL) and not in non-responders. Key limitations include reliance on an in vitro cell line model (THP-1) rather than primary human dendritic cells, lack of an in vivo component, and the correlational nature of many associations. The authors suggest that Tα1's IL-15 pathway activation in dendritic cells could be a candidate mechanism for functional HIV cure strategies, warranting future clinical investigation.

#thymosin alpha-1
Virulence · Mar 2026DOI ↗
In vitro

A multipronged Tα1 reset of CD8<sup>+</sup> T cell cytotoxicity against breast cancer.

This study investigated whether Thymosin α1 (Tα1), an endogenous thymic peptide known to modulate immune function, could enhance CD8+ T cell-mediated killing of breast cancer cells. Researchers isolated CD8+ T cells from peripheral blood of ten healthy donors and tested them under four conditions: unstimulated, CD3/CD28-stimulated, Tα1-treated, or exhaustion-rescue. Cytotoxic activity was assessed against MDA-MB-231 breast cancer cells and CD44+ cancer stem-like cells. The study reported that Tα1 treatment significantly increased cancer cell apoptosis, suppressed tumor cell proliferation, and boosted granzyme B secretion compared to CD3/CD28 stimulation alone. In artificially exhausted T cells, Tα1 partially restored effector function and reduced expression of exhaustion markers PD-1, TIM-3, and LAG-3. Complementary bioinformatic analysis of TCGA-BRCA data (n=1,112) using a four-gene Tα1 Response Index correlated with antigen presentation and cytotoxic gene programs. Key limitations include the small donor sample (n=10), use of healthy donor rather than patient-derived T cells, an in vitro experimental design, and the exploratory nature of the transcriptomic index. Results may not directly translate to in vivo or clinical settings.

#thymosin alpha-1
Human immunology · Jan 2026DOI ↗